

WORKS	HEET: Pre-Review	,
NUMBER	DATE	PAGE
3.205 (HRP-308)	04.24.2024	1 of 1

Determine the laws that apply to the Human Research and indicate in the "Regulatory Oversight" section of the Pre-Review Activity. Determine whether any investigators or research staff are Restricted. If so, list their names and the reasons in the "Restrictions" section of the Pre-Review Activity. Determine whether the Human Research has received all required ancillary reviews and approvals by the appropriate committees and officials. If there is a HIPAA authorization, review using 6.205 (HRP-330) - WORKSHEET: HIPAA Authorization If a HIPAA waiver of authorization is required, grant using 6.201 (HRP-441) - WORKSHEET: HIPAA Waiver of Authorization Determine whether the submission is for a Single-Site Study, Collaborative Study, or Multi-Site Study. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: Complete eIRB+ application Investigator Protocol Determine whether any new information has been provided. (For example, a new risk.) If so, follow 10.001 (HRP-024) SOP: Reportable New Information. INITIAL REVIEW, CONINUING REVIEW, and MODIFICATION (when the modification affects one of the following) If the research involves the use of a device (including a humanitarian use device) use the 8.203 (HRP-307) WORKSHEET: Devices Note any special determinations that need to be made by the convened IRB or Designated Reviewer in the "Special Determinations" section of the Pre-Review Activity. Wote any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity. Delifications of the key personnel Product information for medical devices DHHS-approved sample consent document been submitted attesting compliance with FERPA and PPRA. Investigator brochure for investigational drug Package insert for marketed drugs Institutional Profile Investigator forchure for investigational drug Package insert for m
Determine whether any invostigators or research staff are Restricted. If so, list their names and the reasons in the "Restrictions" section of the Pre-Review Activity. Determine whether the Human Research has received all required ancillary reviews and approvals by the appropriate committees and officials. If the Human Research could be subject to EU GDPR, send for legal counsel review. If there is a HIPAA authorization, review using 6.205 (HRP-330) • WORKSHEET: HIPAA Authorization If a HIPAA waiver of authorization is required, grant using 6.201 (HRP-441) • WORKSHEET: HIPAA Waiver of Authorization Determine whether the submission is for a Single-Site Study, Collaborative Study, or Multi-Site Study. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: Complete eIRB+ application Data collection instruments Investigator Protocol Determine whether any new information has been provided. (For example, a new risk.) If so, follow 10.001 (HRP-024) SOP: Reportable New Information. INITIAL REVIEW, CONINUING REVIEW, and MODIFICATION (when the modification affects one of the following) If the research involves the use of a drug use the 8.202 (HRP-306) WORKSHEET: Drugs and Biologics If the research involves the use of a device (including a humanitarian use device) use the 8.203 (HRP-307) WORKSHEET: Devices Note any special determinations that need to be made by the convened IRB or Designated Reviewer in the "Special Determinations" section of the Pre-Review Activity. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity. Porton of the Review activity and Product information for medical devices Complete sponsor protocol (including DHHS protocol) Product information for medical devices Complete sponsor protocol (including DHHS protocol) Product information for medical devices DHHS-ap
Activity. Determine whether the Human Research has received all required ancillary reviews and approvals by the appropriate committees and officials. If the Human Research could be subject to EU GDPR, send for legal counsel review. If there is a HIPAA authorization, review using 6.205 (HRP-330) - WORKSHEET: HIPAA Authorization If a HIPAA waiver of authorization is required, grant using 6.201 (HRP-441) - WORKSHEET: HIPAA Waiver of Authorization Determine whether the submission is for a Single-Site Study, Collaborative Study, or Multi-Site Study. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: Complete eIRB+ application Data collection instruments Investigator Protocol Written material to be seen or heard by subjects Consent document(s) or script(s) Determine whether any new information has been provided. (For example, a new risk.) If so, follow 10.001 (HRP-024) SOP: Reportable New Information. INITIAL REVIEW, CONINUING REVIEW, and MODIFICATION (when the modification affects one of the following) If the research involves the use of a drug use the 8.202 (HRP-306) WORKSHEET: Drugs and Biologics If the research involves the use of a device (including a humanitarian use device) use the 8.203 (HRP-307) WORKSHEET: Devices Note any special determinations that need to be made by the convened IRB or Designated Reviewer in the "Special Determinations" section of the Pre-Review Activity. If the device meets the abbreviated IDE requirements, note "Non significant device determination" in the "Special Determinations" section of the Pre-Review Activity. Ouglifications of the key personnel Complete sponsor protocol (including DHHS protocol) For the Department of Education (ED) research ensure that a permission letter has been submitted attesting compliance with FERPA and PPRA. Investigator brochure for investigational drug Package insert for marketed drugs
Determine whether the Human Research has received all required ancillary reviews and approvals by the appropriate committees and officials.
If the Human Research could be subject to EU GDPR, send for legal counsel review. If there is a HIPAA authorization, review using 6.205 (HRP-330) - WORKSHEET: HIPAA Authorization If a HIPAA waiver of authorization is required, grant using 6.201 (HRP-441) - WORKSHEET: HIPAA Waiver of Authorization Determine whether the submission is for a Single-Site Study, Collaborative Study, or Multi-Site Study. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: Complete eIRB+ application
If there is a HIPAA authorization, review using 6.205 (HRP-330) - WORKSHEET: HIPAA Authorization If a HIPAA waiver of authorization is required, grant using 6.201 (HRP-441) - WORKSHEET: HIPAA Waiver of Authorization Determine whether the submission is for a Single-Site Study, Collaborative Study, or Multi-Site Study. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: Complete eIRB+ application Data collection instruments Investigator Protocol Written material to be seen or heard by subjects Consent document(s) or script(s) Written material to be seen or heard by subjects Determine whether any new information has been provided. (For example, a new risk.) If so, follow 10.001 (HRP-024) SOP: Reportable New Information. 2 INITIAL REVIEW, CONINUING REVIEW, and MODIFICATION (when the modification affects one of the following) If the research involves the use of a drug use the 8.202 (HRP-306) WORKSHEET: Drugs and Biologics If the research involves the use of a device (including a humanitarian use device) use the 8.203 (HRP-307) WORKSHEET: Devices Note any special determinations that need to be made by the convened IRB or Designated Reviewer in the "Special Determinations" section of the Pre-Review Activity.
If a HIPAA waiver of authorization is required, grant using 6.201 (HRP-441) - WORKSHEET: HIPAA Waiver of Authorization Determine whether the submission is for a Single-Site Study, Collaborative Study, or Multi-Site Study. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: Complete eIRB+ application
If a HIPAA waiver of authorization is required, grant using 6.201 (HRP-441) - WORKSHEET: HIPAA Waiver of Authorization Determine whether the submission is for a Single-Site Study, Collaborative Study, or Multi-Site Study. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: Complete eIRB+ application
Determine whether the submission is for a Single-Site Study, Collaborative Study, or Multi-Site Study. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: Complete eIRB+ application Data collection instruments Written material to be seen or heard by subjects Written material to be seen or heard by subjects Written material to be seen or heard by subjects Determine whether any new information has been provided. (For example, a new risk.) If so, follow 10.001 (HRP-024) SOP: Reportable New Information. Z INITIAL REVIEW, CONINUING REVIEW, and MODIFICATION (when the modification affects one of the following) If the research involves the use of a drug use the 8.202 (HRP-306) WORKSHEET: Drugs and Biologics If the research involves the use of a device (including a humanitarian use device) use the 8.203 (HRP-307) WORKSHEET: Devices Note any special determinations that need to be made by the convened IRB or Designated Reviewer in the "Special Determinations" section of the Pre-Review Activity. If the device meets the abbreviated IDE requirements, note "Non significant device determination" in the "Special Determinations" section of the Pre-Review Activity. Qualifications of the key personnel Product information for medical devices Profunction for medical devices Profunct
Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: Complete eIRB+ application
Investigator Protocol
Consent document(s) or script(s) Determine whether any new information has been provided. (For example, a new risk.) If so, follow 10.001 (HRP-024) SOP: Reportable New Information. INITIAL REVIEW, CONINUING REVIEW, and MODIFICATION (when the modification affects one of the following) If the research involves the use of a drug use the 8.202 (HRP-306) WORKSHEET: Drugs and Biologics If the research involves the use of a device (including a humanitarian use device) use the 8.203 (HRP-307) WORKSHEET: Devices Note any special determinations that need to be made by the convened IRB or Designated Reviewer in the "Special Determinations" section of the Pre-Review Activity. If the device meets the abbreviated IDE requirements, note "Non significant device determination" in the "Special Determinations" section of the Pre-Review Activity. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: Qualifications of the key personnel
Determine whether any new information has been provided. (For example, a new risk.) If so, follow 10.001 (HRP-024) SOP: Reportable New Information. INITIAL REVIEW, CONINUING REVIEW, and MODIFICATION (when the modification affects one of the following) If the research involves the use of a drug use the 8.202 (HRP-306) WORKSHEET: Drugs and Biologics If the research involves the use of a device (including a humanitarian use device) use the 8.203 (HRP-307) WORKSHEET: Devices Note any special determinations that need to be made by the convened IRB or Designated Reviewer in the "Special Determinations" section of the Pre-Review Activity. If the device meets the abbreviated IDE requirements, note "Non significant device determination" in the "Special Determinations" section of the Pre-Review Activity. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: Qualifications of the key personnel Product information for medical devices Complete sponsor protocol (including DHHS protocol) Product information for medical devices DHHS-approved sample consent document been submitted attesting compliance with FERPA and PPRA. Investigator brochure for investigational drug Package insert for marketed drugs
INITIAL REVIEW, CONINUING REVIEW, and MODIFICATION (when the modification affects one of the following)
If the research involves the use of a drug use the 8.202 (HRP-306) WORKSHEET: Drugs and Biologics If the research involves the use of a device (including a humanitarian use device) use the 8.203 (HRP-307) WORKSHEET: Devices Note any special determinations that need to be made by the convened IRB or Designated Reviewer in the "Special Determinations" section of the Pre-Review Activity. If the device meets the abbreviated IDE requirements, note "Non significant device determination" in the "Special Determinations" section of the Pre-Review Activity. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: Qualifications of the key personnel
 □ If the research involves the use of a device (including a humanitarian use device) use the 8.203 (HRP-307) WORKSHEET: Devices □ Note any special determinations that need to be made by the convened IRB or Designated Reviewer in the "Special Determinations" section of the Pre-Review Activity. □ If the device meets the abbreviated IDE requirements, note "Non significant device determination" in the "Special Determinations" section of the Pre-Review Activity. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: □ Qualifications of the key personnel □ Product information for medical devices □ Complete sponsor protocol (including DHHS protocol) □ For the Department of Education (ED) research ensure that a permission letter has been submitted attesting compliance with FERPA and PPRA. □ Investigator brochure for investigational drug □ Package insert for marketed drugs
 □ Note any special determinations that need to be made by the convened IRB or Designated Reviewer in the "Special Determinations" section of the Pre-Review Activity. □ If the device meets the abbreviated IDE requirements, note "Non significant device determination" in the "Special Determinations" section of the Pre-Review Activity. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: □ Qualifications of the key personnel □ Product information for medical devices □ Complete sponsor protocol (including DHHS protocol) □ For the Department of Education (ED) research ensure that a permission letter has been submitted attesting compliance with FERPA and PPRA. □ Investigator brochure for investigational drug □ Package insert for marketed drugs
 □ Note any special determinations that need to be made by the convened IRB or Designated Reviewer in the "Special Determinations" section of the Pre-Review Activity. □ If the device meets the abbreviated IDE requirements, note "Non significant device determination" in the "Special Determinations" section of the Pre-Review Activity. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: □ Qualifications of the key personnel □ Product information for medical devices □ Complete sponsor protocol (including DHHS protocol) □ For the Department of Education (ED) research ensure that a permission letter has been submitted attesting compliance with FERPA and PPRA. □ Investigator brochure for investigational drug □ Package insert for marketed drugs
Activity. If the device meets the abbreviated IDE requirements, note "Non significant device determination" in the "Special Determinations" section of the Pre-Review Activity. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: Qualifications of the key personnel Complete sponsor protocol (including DHHS protocol) Product information for medical devices For the Department of Education (ED) research ensure that a permission letter has been submitted attesting compliance with FERPA and PPRA. Investigator brochure for investigational drug Package insert for marketed drugs
Activity. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: Qualifications of the key personnel Product information for medical devices Complete sponsor protocol (including DHHS protocol) For the Department of Education (ED) research ensure that a permission letter has been submitted attesting compliance with FERPA and PPRA. Investigator brochure for investigational drug Package insert for marketed drugs
Activity. Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: Qualifications of the key personnel Product information for medical devices Complete sponsor protocol (including DHHS protocol) For the Department of Education (ED) research ensure that a permission letter has been submitted attesting compliance with FERPA and PPRA. Investigator brochure for investigational drug Package insert for marketed drugs
Note any missing materials necessary for review in the "Missing Materials" section of the Pre-Review Activity: Qualifications of the key personnel Complete sponsor protocol (including DHHS protocol) DHHS-approved sample consent document DHHS-approved sample consent document Investigator brochure for investigational drug Package insert for marketed drugs
 □ Qualifications of the key personnel □ Complete sponsor protocol (including DHHS protocol) □ DHHS-approved sample consent document □ Investigator brochure for investigational drug □ Product information for medical devices □ For the Department of Education (ED) research ensure that a permission letter has been submitted attesting compliance with FERPA and PPRA. □ Package insert for marketed drugs
 □ Complete sponsor protocol (including DHHS protocol) □ DHHS-approved sample consent document □ Investigator brochure for investigational drug □ Package insert for marketed drugs □ For the Department of Education (ED) research ensure that a permission letter has been submitted attesting compliance with FERPA and PPRA.
 □ DHHS-approved sample consent document □ Investigator brochure for investigational drug □ Package insert for marketed drugs
 □ Investigator brochure for investigational drug □ Package insert for marketed drugs
□ Package insert for marketed drugs
☐ Executed Reliance Agreement(s)
Note missing/inappropriately answered Investigator Protocol sections in the "Missing Materials" section of the Pre-Review Activity:
☐ IRB Review History ☐ Inclusion/Exclusion Criteria ☐ Data Management ☐ Consent Process
□ Objectives □ Compensation for Injury □ Confidentiality □ Consent Documentation
☐ Background ☐ Local Number of Subjects ☐ Provisions to Monitor Data ☐ Vulnerable Populations
☐ Setting ☐ Total Number of Subjects ☐ Withdrawal of Subjects ☐ Drugs or Devices
☐ Resources Available ☐ Study Timelines ☐ Risks to Subjects ☐ Multi-Site Research
☐ Prior Approvals ☐ Study Endpoints ☐ Potential Benefits to Subjects ☐ Community-Based Participatory
□ Study Design □ Procedures Involved □ Provisions to Protect Privacy Research
☐ Recruitment Methods ☐ Data and Specimen Banking ☐ Economic Burden to Subjects ☐ Sharing of Results
"Notes" section of the Pre-Review Activity:
☐ Research is subject to regulations not overseen or conducted by the ☐ There are inadequate provisions to control the device(s)
organization There are inadequate provisions for an investigator held IND
□ Positive financial declaration without a Conflict of Interest report □ There are inadequate provisions for an investigator held IDE
□ Protocol information relates to an item in the list of institutional financial □ External site(s) getting federal funds from the organization does not have a
interests federalwide assurance (FWA)
HUMBORD IEUEROWIUE GAAUROUE II WELL
• ,
□ An IND is required and there is no IND □ The research involves adults unable to consent and statements by the
□ An IND is required and there is no IND □ The research involves adults unable to consent and statements by the investigator and legal counsel regarding which individuals are legally
□ An IND is required and there is no IND □ The research involves adults unable to consent and statements by the □ An IND is required and there is insufficient documentation investigator and legal counsel regarding which individuals are legally □ An IDE/HDE is required and there is no IDE/HDE authorized representatives (<u>LAR</u>) do not match.
□ An IND is required and there is no IND □ The research involves adults unable to consent and statements by the investigator and legal counsel regarding which individuals are legally

□ Confirm that the research meets the criteria for closure and note in the Study Closure Section of the Pre-Review Activity.